Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])

被引：0
|
作者：
Tabernero, J.
Aranda, E.
Gomez, A.
Massuti, B.
Sastre, J.
Abad, A.
Valladares, M.
Rivera, F.
Safont, M.
Diaz-Rubio, E.
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Gen Alicante, Alicante, Spain
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Univ Hosp Germans Trias & Pujol ICO, Barcelona, Spain
[6] Complejo Hosp Univ La Coruna, La Coruna, Spain
[7] Hosp Marques de Valdecilla, Cantabria, Spain
[8] Hosp Gen Valencia, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3501
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MACRO/TTD PHASE III STUDY OF FIRST-LINE XELOX PLUS BEV FOR 6 CYCLES FOLLOWED BY XELOX PLUS BEV OR SINGLE AGENT (S/A) BEV AS MAINTENANCE THERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER
    Aranda, E.
    Tabernero, J.
    Gomez, A.
    Yuste, A.
    Puente, J.
    Abad, A.
    Valladares, M.
    Rivera, F.
    Safont, M.
    de Prado, Martinez P.
    Gallen, M.
    Gonzalez, E.
    Benavides, M.
    Marcuello, E.
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 17 - 17
  • [2] First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
    Diaz-Rubio, Eduardo
    Gomez-Espana, Auxiliadora
    Massuti, Bartomeu
    Sastre, Javier
    Abad, Albert
    Valladares, Manuel
    Rivera, Fernando
    Safont, Maria J.
    Martinez de Prado, Purificacion
    Gallen, Manuel
    Gonzalez, Encarnacion
    Marcuello, Eugenio
    Benavides, Manuel
    Fernandez-Martos, Carlos
    Losa, Ferran
    Escudero, Pilar
    Arrivi, Antonio
    Cervantes, Andres
    Duenas, Rosario
    Lopez-Ladron, Amelia
    Lacasta, Adelaida
    Llanos, Marta
    Tabernero, Jose M.
    Anton, Antonio
    Aranda, Enrique
    ONCOLOGIST, 2012, 17 (01): : 15 - 25
  • [3] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).
    Joseph, Mathew John
    Barnes, Kirk
    Blachly, Ronald
    Kuzur, Michel E.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study
    Yalcin, Suayib
    Uslu, Ruchan
    Dane, Faysal
    Yilmaz, Ugur
    Zengin, Nurullah
    Buyukunal, Evin
    Buyukberber, Suleyman
    Camci, Celalettin
    Sencan, Orhan
    Kilickap, Saadettin
    Ozdener, Fatih
    Cevik, Duygu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
    Peria, F. M.
    Ungari, A. Q.
    Dos Santos, F. N.
    Lins-Almeida, T.
    Nunes, A. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Masi, Gianluca
    Zagonel, Vittorina
    Bergamo, Francesca
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Pinta, Francesco
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Sonaglio, Claudia
    De Stefano, Alfonso
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Bergamo, Francesca
    Gallano, Antonella
    Zagonel, Vittorina
    Ferrari, Laura
    Ongaro, Elena
    Cardellino, Giovanni
    Marcucci, Lorenzo
    Lucchesi, Sara
    Banzi, Maria
    Ciarlo, Andrea
    Miraglio, Emanuele
    Delfanti, Sara
    Corsi, Domenico C.
    Zaniboni, Alberto
    Tonlni, Giuseppe
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC)
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Xu, Hanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345